Care este prețul pentru Sesen Bio, Inc. (SESN)

Prețul pentru Sesen Bio, Inc. (SESN) este $0.6288

Care este capitalizarea de piață pentru Sesen Bio, Inc. (SESN)

Capitalizarea de piață pentru Sesen Bio, Inc. (SESN) este $6.00M

Sesen Bio, Inc. (SESN) Raport P/E

Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

An	Raport P/E	Schimbă
Nu sunt suficiente date pentru perioada selectată.

Raport P/E

Schimbă

Nu sunt suficiente date pentru perioada selectată.

Companie	P/E Ratio	Diferență P/E Ratio	Țara
Vertex Pharmaceuticals Incorporated VRTX.US	29.20	-	US
Argenx SE ARGX.US	30.62	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	18.38	-	BE

Companie

P/E Ratio

Diferență P/E Ratio

Țara